Ionis Pharmaceuticals (NASDAQ: IONS) has experienced a notable increase in its stock price target, rising from $73.00 to $77.00 according to a report released by analysts...
Rhythm Pharmaceuticals (NASDAQ: RYTM) faced a significant downgrade from Zacks Research, moving from a “hold” rating to a “strong sell” rating, as reported on Monday. This...
On November 6, 2023, Wall Street Zen upgraded its rating for Structure Therapeutics (NASDAQ: GPCR) from “sell” to “hold.” This decision reflects a shift in sentiment...
On November 28, 2023, Wall Street Zen upgraded Structure Therapeutics (NASDAQ: GPCR) from a “sell” rating to a “hold” rating. This change comes as a part...
Pharvaris (NASDAQ: PHVS) has recently been upgraded by Wall Street Zen from a “sell” rating to a “hold” rating, reflecting a positive shift in investor sentiment...
On August 16, 2023, Citizens Jmp began coverage of Assembly Biosciences (NASDAQ: ASMB), assigning an “outperform” rating along with a target price of $38.00. This biopharmaceutical...
Assembly Biosciences (NASDAQ: ASMB) received a significant boost as Guggenheim raised its price target for the biopharmaceutical company’s stock from $31.00 to $39.00. This adjustment, reported...
